SCHOLAR ROCK HOLDING CORP (SRRK)
US80706P1030 - Common Stock
Taking everything into account, SRRK scores 2 out of 10 in our fundamental rating. SRRK was compared to 565 industry peers in the Biotechnology industry. SRRK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SRRK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SRRK had negative earnings in the past year.
SRRK had a negative operating cash flow in the past year.
SRRK had negative earnings in each of the past 5 years.
SRRK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRRK has a Return On Assets (-53.30%) which is in line with its industry peers.
SRRK has a Return On Equity of -73.62%. This is comparable to the rest of the industry: SRRK outperforms 55.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.3% | ||
| ROE | -73.62% | ||
| ROIC | N/A |
ROA(3y)-44.72%
ROA(5y)-36.48%
ROE(3y)-67.3%
ROE(5y)-56.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRRK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SRRK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRRK has more shares outstanding
Compared to 5 years ago, SRRK has more shares outstanding
SRRK has a worse debt/assets ratio than last year.
2.2 Solvency
SRRK has an Altman-Z score of 26.05. This indicates that SRRK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 26.05, SRRK belongs to the best of the industry, outperforming 94.48% of the companies in the same industry.
SRRK has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
SRRK's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. SRRK is outperformed by 69.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 26.05 |
ROIC/WACCN/A
WACC11.01%
2.3 Liquidity
SRRK has a Current Ratio of 8.80. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
SRRK has a better Current ratio (8.80) than 75.98% of its industry peers.
SRRK has a Quick Ratio of 8.80. This indicates that SRRK is financially healthy and has no problem in meeting its short term obligations.
SRRK has a better Quick ratio (8.80) than 76.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.8 | ||
| Quick Ratio | 8.8 |
3. Growth
3.1 Past
SRRK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.51%.
The Revenue for SRRK has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.53%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 25.19% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-24.51%
EPS Next 2Y-6.86%
EPS Next 3Y8.06%
EPS Next 5Y25.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SRRK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SRRK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.86%
EPS Next 3Y8.06%
5. Dividend
5.1 Amount
SRRK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCHOLAR ROCK HOLDING CORP
NASDAQ:SRRK (12/27/2024, 3:16:10 PM)
44.44
-1.29 (-2.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.98%
Inst Owner Change2.43%
Ins Owners1.12%
Ins Owner Change-8.16%
Market Cap4.16B
Analysts85.33
Price Target45.01 (1.28%)
Short Float %16.08%
Short Ratio9.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.15%
Min EPS beat(2)-0.55%
Max EPS beat(2)0.24%
EPS beat(4)3
Avg EPS beat(4)8.4%
Min EPS beat(4)-0.55%
Max EPS beat(4)17.02%
EPS beat(8)6
Avg EPS beat(8)17.82%
EPS beat(12)7
Avg EPS beat(12)10.23%
EPS beat(16)7
Avg EPS beat(16)-188.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.66%
PT rev (3m)58.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.28%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 18.47 | ||
| P/tB | 18.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.35
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS2.41
TBVpS2.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.3% | ||
| ROE | -73.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-44.72%
ROA(5y)-36.48%
ROE(3y)-67.3%
ROE(5y)-56.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.5% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.8 | ||
| Quick Ratio | 8.8 | ||
| Altman-Z | 26.05 |
F-Score1
WACC11.01%
ROIC/WACCN/A
Cap/Depr(3y)79.19%
Cap/Depr(5y)150.41%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.53%
EPS Next Y-24.51%
EPS Next 2Y-6.86%
EPS Next 3Y8.06%
EPS Next 5Y25.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.27%
EBIT Next 3Y20.62%
EBIT Next 5YN/A
FCF growth 1Y-8.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.45%
OCF growth 3YN/A
OCF growth 5YN/A